NO20045370L - Anvendelse av docetaxel/doxorubicin/cyklofosfamid i adjuvansterapi av bryst og ovariekreft - Google Patents

Anvendelse av docetaxel/doxorubicin/cyklofosfamid i adjuvansterapi av bryst og ovariekreft

Info

Publication number
NO20045370L
NO20045370L NO20045370A NO20045370A NO20045370L NO 20045370 L NO20045370 L NO 20045370L NO 20045370 A NO20045370 A NO 20045370A NO 20045370 A NO20045370 A NO 20045370A NO 20045370 L NO20045370 L NO 20045370L
Authority
NO
Norway
Prior art keywords
docetaxel
cyclophosphamide
doxorubicin
ovarian cancer
breast
Prior art date
Application number
NO20045370A
Other languages
English (en)
Inventor
Hichem Chakroun
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20045370L publication Critical patent/NO20045370L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Det er beskrevet en ny fremgangsmåte for adjuvansterapi ved behandling av metastatisk bryst- eller ovariekreft, som omfatter adminisfrering av 6 sykluser av docetaxel, doxorubicin og cyklofosfamid til en pasient som har behov for dette, hvor nevnte doseringer har en markert terapeutisk effekt sammenlignet med andre adjuvansterapier.
NO20045370A 2002-05-17 2004-12-08 Anvendelse av docetaxel/doxorubicin/cyklofosfamid i adjuvansterapi av bryst og ovariekreft NO20045370L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38085002P 2002-05-17 2002-05-17
PCT/EP2003/007443 WO2003097164A1 (en) 2002-05-17 2003-05-15 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer

Publications (1)

Publication Number Publication Date
NO20045370L true NO20045370L (no) 2004-12-08

Family

ID=29550025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045370A NO20045370L (no) 2002-05-17 2004-12-08 Anvendelse av docetaxel/doxorubicin/cyklofosfamid i adjuvansterapi av bryst og ovariekreft

Country Status (28)

Country Link
US (2) US20040014694A1 (no)
EP (1) EP1507573A1 (no)
JP (1) JP4773719B2 (no)
KR (1) KR20050000544A (no)
CN (1) CN1652845A (no)
AU (1) AU2003244646B2 (no)
BR (1) BR0310026A (no)
CA (1) CA2486124A1 (no)
CR (1) CR7575A (no)
EC (1) ECSP045433A (no)
HR (1) HRPK20041072B3 (no)
IL (1) IL165214A0 (no)
MA (1) MA27417A1 (no)
ME (2) MEP16308A (no)
MX (1) MXPA04010640A (no)
MY (1) MY146533A (no)
NO (1) NO20045370L (no)
NZ (1) NZ535992A (no)
OA (1) OA12819A (no)
PA (1) PA8574001A1 (no)
RS (1) RS96304A (no)
RU (1) RU2321396C2 (no)
TN (1) TNSN04217A1 (no)
TW (1) TWI374741B (no)
UA (1) UA81628C2 (no)
UY (1) UY27812A1 (no)
WO (1) WO2003097164A1 (no)
ZA (1) ZA200408549B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003222A (es) * 2003-09-25 2006-05-22 Astellas Pharma Inc Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20080085879A1 (en) * 2006-08-31 2008-04-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
EP2694056B1 (en) * 2011-04-01 2019-10-16 AstraZeneca AB Therapeutic treatment
WO2013079964A1 (en) 2011-11-30 2013-06-06 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
KR20160141857A (ko) * 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
WO2017068227A1 (es) * 2015-10-22 2017-04-27 Universidade De Santiago De Compostela Métodos para utilizar reguladores de aumento de la expresión o activación de p53 y/o reguladores de disminución o inhibidores de la expresión de p63-alfa para el tratamiento de nafld (enfermedad de hígado graso no-alcohólico) y/o nash (esteatohepatitis no- alcohólica)
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
WO2018039452A1 (en) * 2016-08-24 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods of treating cancers with chemotherapy with reduced toxicity
WO2018067575A1 (en) * 2016-10-03 2018-04-12 Indiana University Research And Technology Corporation Combination drug therapy reduces parp-1 related dna repair and increases the efficacy of genotoxic agents
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020514412A (ja) * 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
KR20210048483A (ko) * 2018-06-22 2021-05-03 오하이오 스테이트 이노베이션 파운데이션 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
NZ535992A (en) 2008-11-28
MA27417A1 (fr) 2005-07-01
MY146533A (en) 2012-08-15
MEP16308A (en) 2010-06-10
US20070265213A1 (en) 2007-11-15
US20040014694A1 (en) 2004-01-22
HRPK20041072B3 (en) 2007-07-31
CN1652845A (zh) 2005-08-10
OA12819A (en) 2006-07-10
PA8574001A1 (es) 2003-12-19
MXPA04010640A (es) 2005-08-16
EP1507573A1 (en) 2005-02-23
TWI374741B (en) 2012-10-21
TNSN04217A1 (en) 2007-03-12
ECSP045433A (es) 2005-01-03
UA81628C2 (uk) 2008-01-25
JP2005529925A (ja) 2005-10-06
CR7575A (es) 2006-05-10
TW200407152A (en) 2004-05-16
UY27812A1 (es) 2003-11-28
KR20050000544A (ko) 2005-01-05
JP4773719B2 (ja) 2011-09-14
IL165214A0 (en) 2005-12-18
RU2004136984A (ru) 2005-06-27
WO2003097164A1 (en) 2003-11-27
ME00055B (me) 2010-10-10
AU2003244646B2 (en) 2008-08-07
HRP20041072A2 (en) 2005-06-30
RS96304A (en) 2006-10-27
AU2003244646A1 (en) 2003-12-02
RU2321396C2 (ru) 2008-04-10
ZA200408549B (en) 2006-01-25
BR0310026A (pt) 2005-02-15
CA2486124A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
NO20045370L (no) Anvendelse av docetaxel/doxorubicin/cyklofosfamid i adjuvansterapi av bryst og ovariekreft
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
EA202092154A1 (ru) Комбинированная терапия
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
NO20032027D0 (no) Effektive antitumorbehandlinger
BRPI0517976A (pt) métodos de tratamento
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
SE0300098D0 (sv) Use of cyclin D1 inhibitors
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni
PL368686A1 (en) Novel aminobenzoephenones
HUP0301276A2 (hu) Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
GB0220257D0 (en) Vaccine
MD3381G2 (ro) Metodă de tratament al parotiditei cronice la copii
AU2003229876A1 (en) Tumour associated antigens
MXPA05011568A (es) Uso de irinotecan para el tratamiento de cancer recurrente de mama.
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту
TH102680A (th) การใช้โดซีแทกเซล/ดอกโซรูบิซิน/ไซโคลฟอสฟาไมด์ ในการรักษาแบบเสริม
AR043241A1 (es) Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral
MD20010346A (ro) Procedeu de tratare a masei vegetale de salvie de muscat (Salvia Sclarea) si utilizarea ei in tratamentul patologiilor aparatului locomotor
DK1385497T3 (da) Forebyggelse eller behandling af bryst-, prostata- og/eller halscancer med N,N-dimethylglycin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application